You are here

Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder

Last updated on February 21, 2019

FOR MORE INFORMATION
Study Location
Birmingham Research Group Inc.
Birmingham, Alabama, 35216 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Outpatients who have completed double-blind therapy in a phase 3 DVS-233 SR short-term
study for the indication of MDD, including scheduled evaluations, with no major
protocol violations and no study events that, in the opinion of the investigator,
would preclude the subject's entry into the long-term, open-label study.

- Sexually active individuals participating in the study must use a medically acceptable
form of contraception during the trial and for at least 15 days after the last dose of
study drug.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Clinically important abnormalities on baseline physical examination, or any unresolved
clinically significant abnormalities on ECG, laboratory test results, or vital signs
recorded in a previous phase 3 DVS-233 SR short-term study for the indication of MDD.
Any exception must be discussed with and granted by the sponsor.

- Significant risk of suicide based on clinical judgment, including common suicidal
thoughts, and suicide being considered as a possible solution, even without specific
plans or intention.

- Presence of clinically important hepatic or renal disease or other medical disease
that might compromise the study or be detrimental to the subject (eg, clinically
important cardiac arrhythmia, uncontrolled diabetes, uncontrolled hypertension,
seizure disorder, myocardial infarction, neurologic disorder, acute illness,
neoplastic disorder).

NCT01309542
Pfizer
Completed
Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now